Citations

Mayo Clinic

Showing 10 of 108599 citations.

Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel.
Gravis, Gwénaëlle , Liu, Glenn , Fizazi, Karim , Jarrard, David F. , Soulié, M. , Eisenberger, Mario A. , Habibian, Muriel, García, Jorge A. , DiPaola, Robert S. , Boher, Jean‐Marie , Chen, Yu‐Hui , Carducci, Michael A. , Oudard, Stéphane , Joly, Florence , Dreicer, Robert , Hussain, Maha , Kohli, Manish , Vogelzang, Nicholas J. , Picus, Joel , Sweeney, Christopher J. , Gravis, Gwenaelle

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 136-136

10.1200/jco.2017.35.6_suppl.136 Get It

136 Background: Patients with a low burden of metastatic disease and who relapse after localized therapy with curative intent have a longer overall survival. It is unclear whether these patients benefit from early docetaxel (D). Methods: Patients in GETUG-AFU15 (N = 385, median follow-up 84 mo) and CHAARTED (N = 790, median follow up 54 mo) were randomized to ADT alone or ADT + D and outcomes described using the same definition of high volume (HV) and low volume (LV) disease. (HV: visceral metastases and/or 4 or more bone metastases with at least one outside the axis) and whether the patients had prior local therapy or not. Results: Table 1 details across both studies that de novo HV group treated with ADT alone has the shortest overall survival and D has a consistent effect in improving OS. In contrast, in both studies patients with LV disease had a much longer OS with no evidence that D improved OS. Conclusions: There was no apparent survival benefit in CHAARTED and GETUG-15 studies with D for LV whether patients had prior local treatment or not. Across both studies, early D had a consistent effect and improved OS in HV pts especially those with no prior local therapy. Partial Support and drug supply by Sanofi. Clinical trial information: NCT00104715, NCT00309985. [Table: see text]
Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.
Yousefi, Kasra, Deheshi, Samineh, Ross, Ashley E. , Karnes, Jeffrey , Glass, Andrew G., Freedland, Stephen J. , Lam, Lucia L.C., Plessis, Marguerite du, Choeurng, Voleak, Haddad, Zaid , Buerki, Christine, Weinmann, Sheila , Feng, Felix Y. , Spratt, Daniel E. , Schaeffer, Edward M. , Trock, Bruce J , Den, Robert B. , Dicker, Adam P. , Davicioni, Elai , Klein, Eric A.

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 133-133

10.1200/jco.2017.35.6_suppl.133 Get It

133 Background: The genomic classifier, Decipher, has been validated to predict risk of metastasis after radical prostatectomy (RP). However, the cohort size and event rate in the previous studies did not allow for a thorough investigation into performance within individual clinicopathologic or treatment subgroups. In this study, we present the first meta-analysis of the performance of the 22-marker genomic classifier in men with prostate cancer (PCa) post-RP. Methods: MEDLINE, EMBASE, and the Decipher genomic resource information database were searched for published reports of men with PCa treated by RP between 2010 and 2016 where the benefit of the Decipher genomic classifier test was assessed. The primary end point was the ability of Decipher to independently improve prognostication of regional or distant metastasis over routine clinicopathologic factors. Meta-analysis was performed with random-effects modeling, and extent of heterogeneity between studies was determined with the I2 test. Results: Five studies (975 total patients, and 855 with individual patient genomic and clinicopathologic data) were eligible for analysis. The median follow-up was 8 years. All patients had clinical high-risk disease, yet 60.9%, 22.6%, and 16.5% of patients were classified as low, intermediate, and high-risk, respectively by Decipher and had 10-year cumulative incidence rates of metastases of 5.5%, 15.0% and 26.7% (p < 0.001), respectively. Adjusting for standard clinicopathologic variables, on multivariable analysis Decipher remained a statistically significant predictor of metastasis (hazard ratio [HR] 1.30 per 0.1 unit, 95% confidence interval [CI] 1.14-1.47, p < 0.001), and the summary HR for metastasis of Decipher across the 5 studies was 1.52 (95% CI 1.39-1.67) per 0.1 unit. Conclusions: The genomic classifier test, Decipher, has the ability to independently improve prognostication of men post-RP, as well as within nearly all clinicopathologic and treatment subgroups. Strong consideration should be given to incorporating the use of genomic testing in clinical decision making and clinical trials to better individualize treatment.
Long-term aspirin use and intratumoral gene expression in prostate cancer.
Downer, Mary K. , Mucci, Lorelei A. , Stopsack, Konrad H. , Ebot, Ericka M. , Rider, Jennifer R.

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 106-106

10.1200/jco.2017.35.6_suppl.106 Get It

106 Background: Pharmacoepidemiologic studies suggest prognostic benefits of aspirin in prostate cancer. We hypothesized that prostate cancer tissue from regular aspirin users at cancer diagnosis compared to nonusers is characterized by specific transcriptional changes. Methods: We analyzed tumor whole-transcriptome data from men diagnosed with prostate cancer during prospective follow up of the Physicians Health Study 1 (PHS1, n1 = 150), initially a randomized-controlled trial of aspirin for prevention of cardiovascular disease and cancer. We compared the expression of putative aspirin target genes ( PTGS2, CTNNB1, MYC, AXIN2, PTGER3) between regular aspirin users ( ≥ 3 x 324 mg/week) and non-users at cancer diagnosis. We used Gene Set Enrichment Analysis to identify Gene Ontology biological process gene sets (total, 3609) associated with aspirin use. Leading edge genes of ≥ 3 functionally related gene sets were summarized in a meta-gene score. Results were validated among prostate cancer patients from the Health-Professionals Follow-up Study (HPFS, n2 = 254; aspirin use, ≥ 2 x/week). Results: Regular aspirin use was common (65% in PHS1; 45% in HPFS) and not associated with age, stage, and Gleason grade. In PHS1, none of the predefined genes were associated with aspirin use (all p > 0.05). 26 gene sets were downregulated in aspirin users at a false discovery rate (FDR) < 0.25 (9 at FDR < 0.05). 11 gene sets were clustered functionally around ribosome function and protein translation. A “ribosome” score of 96 genes was higher in aspirin users compared to nonusers (difference, 35.5 standard deviations [SD]; p = 0.0001). There was no dose-dependency for cumulative duration of aspirin use before cancer diagnosis ( ptrend = 0.17) or time since stopping use among non-users at diagnosis ( p = 0.32). In HPFS, neither the pre-defined target genes (all p > 0.18) nor the score were associated with aspirin use (difference, –9.8 SD; p = 0.18). Conclusions: Although RNA acetylation and resulting intratumoral gene expression changes due to aspirin use may be biologically plausible, we were unable to corroborate this association in two-long term prospective studies. Short-term trials might assess if aspirin has direct effects on tumor gene expression.
Implications of prostate cancer with diabetes mellitus on patient outcomes and care: A matched case-control study.
Karlin, Nina J. , Verona, Patricia M , Amin, Shailja B , Kosiorek, Heidi , Cook, Curtiss B.

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 101-101

10.1200/jco.2017.35.6_suppl.101 Get It

101 Background: Diabetes mellitus (DM) has been associated with an increased risk of mortality among patients with many types of cancers. The aim of this case-control study was to determine the impact of DM on short-term overall survival in prostate cancer patients, and to examine the impact of prostate cancer on glycemic control in DM. Methods: 276 patients with newly diagnosed prostate cancer from 2007-2014 with DM were identified from the Institutional Cancer Registry and matched to 276 prostate cancer patients without DM according to age and year of prostate cancer diagnosis. The file was linked to the electronic medical record to obtain information on DM and cancer therapies, and laboratory results. Results: The mean age of the entire prostate cancer cohort was 72 years, most (93%) were white, the most common Gleason score (in 52%) was 7, and the majority (56%) were tumor stage 2. No differences in age, race/ethnicity, Gleason score, or tumor stage were detected between patients with and without DM, although DM patients had higher body mass index (P = .031). Among those with DM the mean hemoglobin A1c (HbA1c) was 6.7%. In Kaplan-Meier survival analysis (median follow-up time of 43.7 months), 5-year overall survival was estimated at 88% for DM patients versus 93% in non-DM patients. Hazard ratio (for matched pairs) was 1.64 (95% CI: 0.77-3.46, P = .20). Moreover, mean HbA1c and glucose values among DM cases did not significantly change over 1 year (P ≥ .13). Mean glucose among DM patients was significantly (p < 0.01) higher compared to non-DM patients. Conclusions: DM did not adversely impact survival in prostate cancer patients. In addition, prostate cancer or its treatment does not appear to affect glycemic control. Both patients and their providers can be reassured that the two concurrent diagnoses do not adversely interact to worsen short term outcomes.
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia
Sidana, Surbhi , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Kapoor, Prashant , Go, Ronald S. , Hwa, Yi L. , Leung, Nelson , Fonder, Amie , Hobbs, Miriam, Zeldenrust, Steven R., Russell, Stephen J. , Lust, John A., Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Go, Ronald S , Hwa, Yi Lisa, Leung, Nelson , Fonder, Amie L, Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Russell, Stephen J , Sidana, Surbhi , Dingli, David

American Journal of Hematology | March 29, 2017 | Volume: 92 | Issue: 7 | Pages: 668-673

10.1002/ajh.24745 | PMID 28370486 Get It

Abstract We describe a series of 102 patients diagnosed from January 1, 1990 to December 31, 2015 with Type 1 monoclonal cryoglobulinemia (MoC). Symptoms were seen in 89 (87%) patients, including: cutaneous symptoms in 64 (63%) patients, with purpura (n = 43, 42%) and ulcers/gangrene (n = 35, 34%) being most common; neurological findings in 33 (32%) patients, most frequently sensory neuropathy (n = 24, 24%); vasomotor symptoms, mainly Raynaud's phenomenon in 25 (25%); arthralgias in 24 (24%); and renal manifestations, primarily glomerulonephritis in 14 (14%) patients. An underlying lymphoproliferative disorder was identified in 94 (92%) subjects; MGUS—39, myeloma—20, lymphoplasmacytic lymphoma—21 and others—14. Treatment was initiated in 73 (72%) patients, primarily for cryoglobulinemia‐related symptoms in 57. Treatment regimens consisted of: steroids ± alkylating agents in 29 (40%), novel myeloma therapies in 16 (22%), rituximab with alkylating agents in 12 (16%) and rituximab ± steroids in 11 (15%) patients; 22 patients received plasmapheresis. Six patients underwent autologous stem cell transplant. Cryocrit at treatment initiation, change in cryocrit and time to nadir cryocrit were predictive of symptom improvement. Treatment directed toward the underlying clonal disorder resulted in improvement (n = 47) or stabilization (n = 16) of symptoms in the majority of patients and disappearance of cryoglobulin in over one‐half.
Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis
Chew, Jeannie , Stankowski, Jeannette N. , Hayes, Lindsey R. , Zhang, Yong‐Jie , Prudencio, Mercedes , Carlomagno, Yari , Daughrity, Lillian M. , Jansen‐West, Karen , Perkerson, Emilie A., O’Raw, Aliesha D. , Cook, Casey , Pregent, Luc , Belzil, Véronique , Blitterswijk, Marka van , Tabassian, Lilia J., Lee, Chris W. , Yue, Mei, Tong, Jimei, Song, Yuping , Castanedes‐Casey, Monica , Rousseau, Linda , Phillips, Virginia , Rademakers, Rosa , Fryer, John Denis , Rush, Beth , Pedraza, Otto , Caputo, Ana M., Desaro, Pamela , Palmucci, Carla, Robertson, A. , Diehl, Nancy N. , Wiggs, Edythe, Tierney, Michael , Braun, Laura, Farren, Jennifer, Lacomis, David , Fournier, Christina , McCluskey, Leo, Elman, Lauren , Toledo, Jon B. , McBride, Jennifer D. , Tiloca, Cinzia , Morelli, Claudia , Poletti, Barbara , Solca, Federica , Wuu, Joanne , Jockel‐Balsarotti, Jennifer , Rigo, Frank , Ambrose, Christine, Yang, Weixing , Raitcheva, Denitza , Antognetti, Giovanna, McCampbell, Alexander , Boxer, Adam L. , Brown, Robert H. , Bowser, Robert , Miller, Timothy M. , Trojanowski, John Q. , Hu, William T. , Ratti, Antonia , Benatar, Michael , Glass, Jonathan D. , Floeter, Mary Kay, Petrucelli, Leonard , Gendron, Tania F. , Zhang, Yong-Jie , Prudencio, Mercedes , Carlomagno, Yari , Jansen-West, Karen, O'Raw, Aliesha , Pregent, Luc , Belzil, Veronique , van Blitterswijk, Marka , Castanedes-Casey, Monica , Rousseau, Linda , Phillips, Virginia , Rademakers, Rosa , Fryer, John D., Desaro, Pamela , Palmucci, Carla , Robertson, Amelia , Lacomis, David , Ladha, Shafeeq , Tiloca, Cinzia , Poletti, Barbara , Solca, Federica , Prelle, Alessandro , Jockel-Balsarotti, Jennifer , Yang, Weixing , Raitcheva, Denitza , Benatar, Michael , Silani, Vincenzo , Boylan, Kevin B, Petrucelli, Leonard , Dickson, Dennis W. , Heckman, Michael G. , Ladha, Shafeeq , Datta, Abhishek , Swieten, John C. van , Miller, Bruce L. , Grossman, Murray , Berry, James D. , Traynor, Bryan J. , Disney, Matthew D. , Silani, Vincenzo , Rothstein, Jeffrey D. , Boylan, Khrista , Hu, William T.

Science Translational Medicine | March 29, 2017 | Volume: 9 | Issue: 383 | Pages: No page available

10.1126/scitranslmed.aai7866 | PMID 28356511 Get It

Poly(GP) proteins are a promising pharmacodynamic marker for developing and testing therapeutics for treating C9ORF72 -associated amyotrophic lateral sclerosis.
Faculty Opinions recommendation of Bio-SCoRes: A Smorgasbord Architecture for Coreference Resolution in Biomedical Text.
Liu, Hongfang

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 29, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726190806.793529992 Get It

Clinical outcomes following inpatient penicillin allergy testing: A systematic review and meta‐analysis
Sacco, Keith , Bates, Alexander , Brigham, Tara , Imam, J. Saadi , Burton, M. Caroline , Sacco, Keith A , Brigham, T J , Bates, A.

Allergy | March 29, 2017 | Volume: 72 | Issue: 9 | Pages: 1288-1296

10.1111/all.13168 | PMID 28370003 Get It

Abstract Background A documented penicillin allergy is associated with increased morbidity including length of hospital stay and an increased incidence of resistant infections attributed to use of broader‐spectrum antibiotics. The aim of the systematic review was to identify whether inpatient penicillin allergy testing affected clinical outcomes during hospitalization. Methods We performed an electronic search of Ovid MEDLINE /PubMed, Embase, Web of Science, Scopus, and the Cochrane Library over the past 20 years. Inpatients having a documented penicillin allergy that underwent penicillin allergy testing were included. Results Twenty‐four studies met eligibility criteria. Study sample size was between 24 and 252 patients in exclusively inpatient cohorts. Penicillin skin testing ( PST ) with or without oral amoxicillin challenge was the main intervention described (18 studies). The population‐weighted mean for a negative PST was 95.1% [ CI 93.8‐96.1]. Inpatient penicillin allergy testing led to a change in antibiotic selection that was greater in the intensive care unit (77.97% [ CI 72.0‐83.1] vs 54.73% [ CI 51.2‐58.2], P <.01). An increased prescription of penicillin (range 9.9%‐49%) and cephalosporin (range 10.7%‐48%) antibiotics was reported. Vancomycin and fluoroquinolone use was decreased. Inpatient penicillin allergy testing was associated with decreased healthcare cost in four studies. Conclusions Inpatient penicillin allergy testing is safe and effective in ruling out penicillin allergy. The rate of negative tests is comparable to outpatient and perioperative data. Patients with a documented penicillin allergy who require penicillin should be tested during hospitalization given its benefit for individual patient outcomes and antibiotic stewardship.
The Systemic Synuclein Sampling Study: Toward a Biomarker for Parkinson’s Disease
Visanji, Naomi P. , Mollenhauer, Brit , Beach, Thomas G. , Coffey, Christopher S. , Kopil, Catherine , Dave, Kuldip D. , Chahine, Lana M. , Jennings, Danna , (S4), the Systemic Synuclein Sampling Study, Adler, Charles H. , Foroud, Tatiana , (S4), the Systemic Synuclein Sampling Study, Visanji, Naomi P

Biomarkers in Medicine | March 29, 2017 | Volume: 11 | Issue: 4 | Pages: 359-368

10.2217/bmm-2016-0366 | PMID 28353371 Get It

Mackinac: a bridge between ModelSEED and COBRApy to generate and analyze genome-scale metabolic models
Mundy, Michael , Mendes‐Soares, Helena , Chia, Nicholas , Chia, Nicholas

Bioinformatics | March 29, 2017 | Volume: 33 | Issue: 15 | Pages: 2416-2418

10.1093/bioinformatics/btx185 | PMID 28379466 Get It

Abstract Summary Reconstructing and analyzing a large number of genome-scale metabolic models is a fundamental part of the integrated study of microbial communities; however, two of the most widely used frameworks for building and analyzing models use different metabolic network representations. Here we describe Mackinac, a Python package that combines ModelSEED’s ability to automatically reconstruct metabolic models with COBRApy’s advanced analysis capabilities to bridge the differences between the two frameworks and facilitate the study of the metabolic potential of microorganisms. Availability and Implementation This package works with Python 2.7, 3.4, and 3.5 on MacOS, Linux and Windows. The source code is available from https://github.com/mmundy42/mackinac.